Related Experiment Video
Updated: Jul 16, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus
Christoph Münch1, Pedros Anagnostou, Robert Meyer
1Department of Neurology, Jewish Hospital Berlin, Berlin, Germany. muench@jkb-online.de
Abstract:
The authors report a 57-year-old patient with chronic inflammatory demyelinating polyneuropathy (CIDP) associated with diabetes mellitus (DM) who was treated successfully with rituximab. The B lymphocyte suppression using rituximab was followed 4 weeks later by neurological improvement and a stable disease course of over 10 months. We suggest that rituximab may be a treatment option in CIDP increasingly less responsive to intravenous immunoglobulin, particularly in patients with concurrent DM.
Related Concept Videos
Diabetic Neuropathy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Diabetic Nephropathy
Diabetic Retinopathy
Type I Diabetes I: Introduction